SUZHOU, March 14, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the phase I clinical study data (study number: JSKN003-101) of the HER2 double antibody conjugate drug JSKN003 for treating advanced HER2-expressing solid tumors in Australia (study number:) was selected for the 2024 American Association for Cancer Research Annual Meeting (AACR 2024) and will be announced in the form of a poster.
The AACR Annual Conference is one of the oldest and largest scientific conferences in the world. It focuses on all aspects of high-quality and innovative oncology research and focuses on cutting-edge research results in the field of oncology. This year's AACR Annual Meeting will be held on April 5-10, 2024, local time in San Diego, USA.
Subject:Safety and efficacy of JSKN003 for the treatment of advanced/metastatic solid tumors: first dose-escalating, multicenter, open phase I study in humans
Summary ID:CT179
Display format:poster
Exhibition location:Poster Section 48
Key Researchers:Claire Beecroft
Poster presentation time:April 9, 2024, 9:00 AM - 12:30 AM EST
JSKN003-101 is an open, multicenter, dose escalation and dose expansion phase I clinical study conducted in Australia to evaluate the safety, tolerability, and initial efficacy of JSKN003 in treating advanced solid tumors, and to determine the recommended phase II dose (RP2D). The AACR conference reported the dose-escalation period (Ia) study data for this study.
The study completed administration of the first patient in September 2022, enrolled patients with dose escalation in October 2023, and first published preliminary data in November 2023, showing initial efficacy and good tolerability. The updated results of this study will be published at this AACR annual meeting.
regardingJSKN003
JSKN003 is a novel antibody conjugation drug (ADC) targeting the HER2 double epitope. It was independently developed by Corning Jerry using a unique sugar fixed-point conjugation platform. JSKN003 binds to HER2 on the surface of tumor cells and releases topoisomerase I inhibitors through HER2-mediated cellular endocytosis, thereby exerting an anti-tumor effect. Preclinical studies have shown that JSKN003 has better serum stability, stronger bystander killing effect, and similar tumor killing activity compared to similar drugs, effectively expanding the treatment window. Currently, JSKN003 is carrying out a number of clinical studies in Australia and China, and it has entered phase III clinical stage in China for breast cancer with low HER2 expression.
About Corning Jerry
Corning Jerry is an innovative biopharmaceutical company dedicated to the discovery, development, production and commercialization of world-class anti-tumor drugs to provide patients with innovative biologic therapies. On December 12, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (stock code: 9966.HK).
Corning Jerry has created a biomacromolecular drug development and production technology platform with independent intellectual property rights, such as protein/antibody engineering, antibody screening, and multi-module/multifunctional antibody modification. A product pipeline with significant differentiation advantages and strong international competitiveness has been created, covering innovative anti-tumor drugs such as single-domain antibody/monoclonal antibodies, multi-functional antibodies and antibody conjugates: 1 product, KN035 (the world's first subcutaneous PD- (L) 1 inhibitor, Envolimab injection, product name: Enweida) was approved for marketing in China in 2021, making it a widely accessible drug for cancer patients; 3 products are in late clinical development; HER2 double antibody KN026 was recognized as a breakthrough therapy by China's NMPA. In addition, the company has a rich early development pipeline, and 2 new drug molecules have already entered the clinical research stage.
“Kangda patients, Regis family”. Corning Jerry has always focused on unmet clinical needs and continues to develop safe, affordable, and globally competitive anti-tumor drugs to benefit patients.